Key Points
- CEO insider buying: Tim Jasper Knotnerus purchased 5,000 AgomAb Therapeutics shares at an average of $8.70, increasing his position by 29.72% to 21,823 shares. He also bought 6,000 shares the previous day.
- Stock and earnings: AGMB opened at $8.80, versus a 12-month range of $7.97 to $17.82. The company reported a quarterly loss of $0.46 per share, with analysts expecting a full-year loss of $1.76 per share.
- Analyst outlook: Seven analysts rate the stock Buy and one rates it Hold, producing a “Moderate Buy” consensus and a $37.50 average price target, well above the current share price.
AgomAb Therapeutics NV (NASDAQ:AGMB - Get Free Report) CEO Tim Jasper Knotnerus purchased 5,000 shares of AgomAb Therapeutics stock in a transaction dated Tuesday, October 6th. The shares were purchased at an average cost of $8.70 per share, with a total value of $43,500.00. Following the acquisition, the chief executive officer owned 21,823 shares of the company's stock, valued at approximately $189,860.10. This trade represents a 29.72% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Tim Jasper Knotnerus also recently made the following trade(s):
- On Monday, October 5th, Tim Jasper Knotnerus acquired 6,000 shares of AgomAb Therapeutics stock. The shares were acquired at an average price of $8.48 per share, with a total value of $50,880.00.
AgomAb Therapeutics Stock Performance
AGMB opened at $8.80 on Thursday. AgomAb Therapeutics NV has a 12 month low of $7.97 and a 12 month high of $17.82. The stock's 50 day moving average price is $12.75 and its 200 day moving average price is $11.97.
AgomAb Therapeutics (NASDAQ:AGMB - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.46) EPS for the quarter. On average, equities analysts expect that AgomAb Therapeutics NV will post -1.76 EPS for the current fiscal year.
Analysts Set New Price Targets
A number of brokerages have issued reports on AGMB. B. Riley Financial assumed coverage on AgomAb Therapeutics in a research note on Thursday, July 23rd. They set a "buy" rating and a $34.00 price target for the company. Piper Sandler began coverage on AgomAb Therapeutics in a report on Tuesday, August 25th. They set an "overweight" rating and a $60.00 target price on the stock. Cantor Fitzgerald began coverage on shares of AgomAb Therapeutics in a research report on Wednesday, August 19th. They issued an "overweight" rating on the stock. HC Wainwright reissued a "buy" rating on shares of AgomAb Therapeutics in a report on Wednesday, September 16th. Finally, Wall Street Zen lowered shares of AgomAb Therapeutics from a "hold" rating to a "sell" rating in a research report on Sunday, September 27th. Seven research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $37.50.
Check Out Our Latest Stock Analysis on AGMB
AgomAb Therapeutics Company Profile
(
Get Free Report)
Agomab Therapeutics N.V. is a clinical-stage biotechnology company developing antibody-based medicines designed to activate biological pathways involved in tissue repair and regeneration. The company focuses on serious diseases in which restoring or rebuilding damaged tissue could provide therapeutic benefit.
Agomab's lead program, AGMB-129, is an investigational, gut-restricted agonist of fibroblast growth factor receptor 1c (FGFR1c) being developed for inflammatory bowel disease, including Crohn's disease.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
